Positron Emission Tomography in Alzheimer‘s Disease: Early Prediction and Differentiation

• Kung HC , HoyertDL, XuJ, MurphySL: Deaths: final data for 2005.Natl Vital Stat. Rep.56(10), 1–120 (2008).
   PubMedGoogle Scholar
• McKhann G , DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM: Clinical diagnosis of Alzheimer‘s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer‘s Disease.Neurology34, 939–944 (1984).
   PubMed Web of Science ®Google Scholar
• Hebert LE , ScherrPA, BieniasJL, BennettDA, EvansDA: Alzheimer disease in the US population: prevalence estimates using the 2000 census.Arch. Neurol.60(80), 1119–1122 (2003).
   PubMedGoogle Scholar
• Mirra SS , HeymanA, McKeelDet al.: The Consortium to Establish a Registry for Alzheimer‘s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer‘s disease.Neurology41, 479–486 (1991).
   PubMed Web of Science ®Google Scholar
• Price JL , MorrisJC: Tangles and plaques in nondemented aging and ‘preclinical‘ Alzheimer‘s disease.Ann. Neurol.45, 358–368 (1999).
   PubMed Web of Science ®Google Scholar
• Braak H , BraakE: Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis.Acta Neuropathol.92, 197–201 (1996).
   PubMed Web of Science ®Google Scholar
• Delacourte A , DavidJP, SergeantNet al.: The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer‘s disease.Neurology52, 1158–1165 (1999).
   PubMed Web of Science ®Google Scholar
• Morris JC , StorandtM, McKeelDWet al.: Cerebral amyloid deposition and diffuse plaques in ‘normal‘ aging: evidence for presymptomatic and very mild Alzheiemer‘s disease.Neurology46, 707–719 (1996).
   PubMed Web of Science ®Google Scholar
• Braak H , BraakE: Neuropathological stageing of Alzheimer-related changes.Acta Neuropathologica82, 239–259 (1991).
   PubMed Web of Science ®Google Scholar
• Morrison JH , HofPR: Life and death of neurons in the aging brain.Science278, 412–419 (1997).
   PubMed Web of Science ®Google Scholar
• Hyman BT , Van Hoesen GW, Damasio AR, Barnes CL: Alzheimer‘s disease: cell-specific pathology isolates the hippocampal formation. Science225, 1168–1170 (1984).
   PubMed Web of Science ®Google Scholar
• Etiene D , KraftJ, GanjuNet al.: Cerebrovascular pathology contributes to the heterogeneity of Alzheimer‘s disease.J. Alz. Dis.1(2), 119–134 (1998).
   PubMedGoogle Scholar
• Snowdon DA , GreinerLH, MortimerJAet al.: Brain infarction and the clinical expression of Alzheimer‘s disease: the Nun study.JAMA277(10), 813–817(1997).
   PubMed Web of Science ®Google Scholar
• Arriagada PV , MarzloffK, HymanBT: Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer‘s disease.Neurology42, 1681–1688 (1992).
   PubMed Web of Science ®Google Scholar
• Giannakopoulos P , HofPR, MottierS, MichelJP, BourasC: Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population.Acta Neuropathol.87, 456–468 (1994).
   PubMed Web of Science ®Google Scholar
• Ulrich J : Alzheimer changes in nondemented patients younger than sixty-five: Possible early stages of Alzheimer‘s disease and senile dementia of Alzheimer type.Ann. Neurol.17, 273–277 (1985).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ : Alzheimer‘s disease: genotypes, phenotype, and treatments.Science275, 630–631 (1997).
   PubMed Web of Science ®Google Scholar
• Lambert MP , BarlowAK, ChromyBAet al.: Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins.Proc. Natl Acad. Sci. USA95(11), 6448–6453 (1998).
   PubMed Web of Science ®Google Scholar
• Consensus Working Group: Consensus report of the Working Group on: ‘Molecular and Biochemical Markers of Alzheimer‘s Disease‘. The Ronald and Nancy Reagan Research Institute of the Alzheimer‘s Association and the National Institute on Aging. Neurobiol. Aging19, 109–116 (1998).
   PubMed Web of Science ®Google Scholar
• Nestor PJ , ScheltensP, HodgesJR: Advances in the early detection of Alzheimer‘s disease.Nat. Med.10, S34-S41 (2004).
   PubMed Web of Science ®Google Scholar
• de Leon MJ , McRaeT, TsaiJRet al.: Abnormal cortisol response in Alzheimer‘s disease linked to hippocampal atrophy.Lancet2, 391–392 (1988).
   PubMed Web of Science ®Google Scholar
• de Leon MJ , GeorgeAE, StylopoulosLA, SmithG, MillerDC: Early marker for Alzheimer‘s disease: the atrophic hippocampus.Lancet2, 672–673 (1989).
   PubMed Web of Science ®Google Scholar
• Jack CR , PetersenRC, XuY, O‘BrienPC, SmithGE, IvnikRJ: Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.Neurology55, 484–489 (2000).
   PubMed Web of Science ®Google Scholar
• Rusinek H , De Santi S, Frid Det al.: Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology229, 691–696 (2003).
   PubMed Web of Science ®Google Scholar
• den Heijer T , GeerlingsMI, HoebeekFE, HofmanA, KoudstaalPJ, BretelerM: Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people.Arch. Gen. Psychiat.63, 57–62 (2006).
   PubMed Web of Science ®Google Scholar
• O‘Sullivan M , NgoE, ViswanathanAet al.: Hippocampal volume is an independent predictor of cognitive performance in CADASIL.Neurobiol. AgingDOI: 10.1016/j.neurobiolaging.2007.09.002 (2008) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Blennow K , de Leon MJ, Zetterberg H: Alzheimer‘s disease. Lancet Neurology368, 387–403 (2006).
   Google Scholar
• Sokoloff L : Relation between physiological functions and energy metabolism in the central nervous system.J. Neurochem.29, 13–26 (1977).
   PubMed Web of Science ®Google Scholar
• Magistretti PJ , PellerinL, RothmanDL, ShulmanRG: Energy on demand.Science283, 496–497 (1999).
   PubMed Web of Science ®Google Scholar
• Attwell D , Iadecola C; The neural basis of functional brain imaging signals. Trends Neurosci.25, 621–625 (2002).
   PubMed Web of Science ®Google Scholar
• Malonek D , GrinvaldA: Interactions between electrical activity and cortical microcirculation revealed by imaging spectroscopy: implications for functional brain mapping.Science272, 551–554 (1996).
   PubMed Web of Science ®Google Scholar
• Rocher AB , ChaponF, BlaizotX, Baron J-C, Chavoix C: Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage20, 1894–1898 (2004).
   Web of Science ®Google Scholar
• Magistretti PJ , PellerinL: The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies.Mol. Psychiatry1, 445–452 (1996).
   PubMed Web of Science ®Google Scholar
• Pellerin L , MagistrettiPJ: Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization.Proc. Natl Acad. Sci. USA91(22), 10625–10629 (1994).
   PubMed Web of Science ®Google Scholar
• Mosconi L : Brain glucose metabolism in the early and specific diagnosis of Alzheimer‘s disease.Eur. J. Nucl. Med.32, 486–510 (2005).
   Google Scholar
• Friedland RP , BudingerTF, GanzEet al.: Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F] fluorodeoxyglucose.J. Comput. Assist. Tomogr.7, 590–598 (1983).
   PubMed Web of Science ®Google Scholar
• Frackowiak RSJ , PozzilliC, LeggNJet al.: A prospective study of regional cerebral blood flow and oxygen utilization in dementia using positron emission tomography and oxygen-15.J. Cereb. Blood Flow Metab.1, S453–S454 (1981).
   Google Scholar
• Minoshima S , GiordaniB, BerentS, FreyKA, FosterNL, KuhlDE: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer‘s disease.Ann. Neurol.42, 85–94 (1997).
   PubMed Web of Science ®Google Scholar
• Ferris SH , de Leon MJ, Wolf APet al.: Positron emission tomography in the study of aging and senile dementia. Neurobiol. Aging1, 127–131 (1980).
   PubMed Web of Science ®Google Scholar
• Kim EJ , ChoSS, JeongYet al.: Glucose metabolism in early onset versus late onset Alzheimer‘s disease: an SPM analysis of 120 patients.Brain128, 1790–1801 (2005).
   PubMed Web of Science ®Google Scholar
• Foster NL , ChaseTN, MansiLet al.: Cortical abnormalities in Alzheimer‘s disease.Ann. Neurol.66, 649–654 (1984).
   Google Scholar
• Mazziotta JC , PhelpsME: Positron emission tomography studies of the brain. Positron Emission Tomography & Autoradiography. In: Principles & Applications for the Brain & Heart. PhelpsME, MazziottaJC, SchelbertH (Eds). Raven Press, NY, USA493–579 (1986).
   Google Scholar
• Herholz K , SalmonE, PeraniDet al.: Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.Neuroimage17, 302–316 (2002).
   PubMed Web of Science ®Google Scholar
• Silverman DHS , SmallGW, ChangCYet al.: Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome.JAMA286, 2120–2127 (2001).
   PubMed Web of Science ®Google Scholar
• Szelies B , MielkeR, HerholzK, Heiss W-D: Quantitative topographical EEG compared with FDG PET for classification of vascular and degenerative dementia. Electroencephalogr. Clin. Neurophysiol.91(2), 131–139 (1994).
   PubMedGoogle Scholar
• de Leon MJ , McRaeT, RusinekHet al.: Cortisol reduces hippocampal glucose metabolism in normal elderly but not in Alzheimer‘s disease.J. Clin. Endocrinol. Metab.82, 3251–3259 (1997).
   PubMed Web of Science ®Google Scholar
• Ouchi Y , NobezawaS, OkadaH, YoshikawaE, FutatsubashiM, KanekoM: Altered glucose metabolism in the hippocampal head in memory impairment.Neurology51, 136–142 (1998).
   PubMed Web of Science ®Google Scholar
• de Leon MJ , ConvitA, WolfOTet al.: Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).Proc. Natl Acad. Sci. USA98, 10966–10971 (2001).
   PubMed Web of Science ®Google Scholar
• De Santi S , de Leon MJ, Rusinek Het al.: Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging22, 529–539 (2001).
   PubMed Web of Science ®Google Scholar
• Nestor PJ , FryerTD, SmielewskiP, HodgesJR: Limbic hypometabolism in Alzheimer‘s disease and mild cognitive impairment.Ann. Neurol.54, 343–351 (2003).
   PubMed Web of Science ®Google Scholar
• Mosconi L , TsuiWH, De Santi S: Reduced hippocampal metabolism in mild cognitive impairment and Alzheimer‘s disease: automated FDG-PET image analysis. Neurology64, 1860–1867 (2005).
   PubMed Web of Science ®Google Scholar
• Mosconi L , De Santi S, Li Yet al.: Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer‘s disease using FDG-PET. Eur. J. Nucl. Med.33, 210–221 (2006).
   Google Scholar
• Mosconi L , De Santi S, Li Jet al.: Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol. Aging29, 676–692 (2008).
   PubMed Web of Science ®Google Scholar
• Mosconi L , TsuiWH, RusinekHet al.: Quantitation, regional vulnerability and kinetic modeling of brain glucose metabolism in mild Alzheimer‘s disease.Eur. J. Nucl. Med. Mol. Imaging34, 1467–1479 (2007).
   PubMed Web of Science ®Google Scholar
• de Leon MJ , GeorgeAE, GolombJet al.: Frequency of hippocampal formation atrophy in normal aging and Alzheimer‘s disease.Neurobiol. Aging18, 1–11 (1997).
   PubMed Web of Science ®Google Scholar
• Chetelat G , DesgrangesB, LandeauBet al.: Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer‘s disease.Brain131(1), 60–71 (2007).
   PubMedGoogle Scholar
• Tanzi RE , BertramL: New frontiers in Alzheimer‘s disease genetics.Neuron32, 181–184 (2001).
   PubMed Web of Science ®Google Scholar
• Kennedy AM , NewmanSK, FrackowiakRSet al.: Chromosome 14 linked familial Alzheimer‘s disease. A clinico-pathological study of a single pedigree.Brain118, 185–205 (1995).
   PubMed Web of Science ®Google Scholar
• Kennedy AM , FrackowiakRSJ, NewmanSKet al.: Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer‘s disease.Neurosci. Lett.186, 17–20 (1995).
   PubMed Web of Science ®Google Scholar
• Mosconi L , SorbiS, de Leon MJet al.: Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer‘s disease. J. Nucl. Med.47, 1778–1786 (2006).
   PubMed Web of Science ®Google Scholar
• Petersen RC , StevensJC, GanguliM, TangalosEG, CummingsJL, DeKoskyST: Practice parameter: Early detection of dementia: mild cognitive impiarment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology56, 1133–1142 (2001).
   PubMed Web of Science ®Google Scholar
• Gauthier S , ReisbergB, ZaudigMet al.: Mild cognitive impairment.Lancet367(9518), 1262–1270 (2006).
   PubMed Web of Science ®Google Scholar
• Herholz K , NordbergA, SalmonEet al.: Impairment of neocortical metabolism predicts progression in Alzheimer‘s disease.Dement. Geriatr. Cogn. Disord.10, 494–504 (1999).
   PubMed Web of Science ®Google Scholar
• Arnaiz E , JelicV, AlmkvistOet al.: Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment.NeuroReport12, 851–855 (2001).
   PubMed Web of Science ®Google Scholar
• Chetelat G , DesgrangesB, De La Sayette V, Viader F, Eustache F, Baron JC: Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer‘s disease?. Neurology60, 1374–1377 (2003).
   PubMed Web of Science ®Google Scholar
• Drzezga A , LautenschlagerN, SiebnerHet al.: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer‘s disease: a PET follow-up study.Eur. J. Nucl. Med. Mol. Imaging30, 1104–1113 (2003).
   PubMed Web of Science ®Google Scholar
• Drzezga A , GrimmerT, RiemenschneiderMet al.: Prediction of individual outcome in MCI by means of genetic assessment and 18F-FDG PET.J. Nucl. Med.46, 1625–1632 (2005).
   PubMed Web of Science ®Google Scholar
• Anchisi D , BorroniB, FranceschiMet al.: Heterogeneity of brain glucose metaboism in mild cognitive impairment and clinical progression to Alzheimer disease.Arch. Neurol.62, 1728–1733 (2005).
   PubMedGoogle Scholar
• Haxby JV , GradyCL, KossEet al.: Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type.Arch. Neurol.47, 753–760 (1990).
   PubMedGoogle Scholar
• Reed BR , JagustWJ, SeabJP, OberBA: Memory and regional cerebral blood flow in mildly symptomatic Alzheimer‘s disease.Neurol.39, 1537–1539 (1989).
   PubMed Web of Science ®Google Scholar
• Berent S , GiordaniB, FosterNet al.: Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer‘s disease.J. Psychiat. Res.33, 7–16 (1999).
   PubMed Web of Science ®Google Scholar
• Mosconi L , PeraniD, SorbiSet al.: MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.Neurology63, 2332–2340 (2004).
   PubMed Web of Science ®Google Scholar
• Petersen RC , SmithGE, WaringSC, IvnikRJ, TangalosEG, KokmenE: Mild cognitive impairment: clinical characterization and outcome.Arch. Neurol.56, 303–308 (1999).
   PubMed Web of Science ®Google Scholar
• Jagust WJ , GitchoA, SunF, KuczynskiB, MungasD, HaanM: Brain imaging evidence of preclinical Alzheimer‘s disease in normal aging.Ann. Neurol.59, 673–681 (2006).
   PubMed Web of Science ®Google Scholar
• Skurk T , Alberti-HuberC, HerderC, HaunerH: Relationship between adipocyte size and adipokine expression and secretion.J. Clin. Endocrinol. Metab.92(3), 1023–1033 (2007).
   PubMed Web of Science ®Google Scholar
• Corder EH , SaundersAM, StrittmatterWJet al.: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer‘s disease in late onset families.Science261, 921–923 (1993).
   PubMed Web of Science ®Google Scholar
• Farrer LA , CupplesLA, HainesJLet al.: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease.JAMA278, 1349–1356 (1997).
   PubMed Web of Science ®Google Scholar
• Laws SM , HoneE, GandyS, MartinsRN: Expanding the association between the APOEgene and the risk of Alzheimer‘s disease: possible roles for APOE promoter polymorphisms and alterations in APOEtranscription.J. Neurochem.84, 1215–1236 (2003).
   PubMed Web of Science ®Google Scholar
• Small GW , MazziottaJC, CollinsMTet al.: Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.JAMA273, 942–947 (1995).
   PubMed Web of Science ®Google Scholar
• Reiman EM , CaselliRJ, YunLSet al.: Preclinical evidence of Alzheimer‘s disease in persons homozygous for the E4 allele for apolipoprotein E.N. Engl. J. Med.334, 752–758 (1996).
   PubMed Web of Science ®Google Scholar
• Small GW , ErcoliLM, SilvermanDHSet al.: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer‘s disease.Proc. Natl Acad. Sci. USA97, 6037–6042 (2000).
   PubMed Web of Science ®Google Scholar
• Reiman EM , CaselliRJ, ChenK, AlexanderGE, BandyD, FrostJ: Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatmentsto prevent Alzheimer‘s disease.Proc. Natl Acad. Sci. USA98, 3334–3339 (2001).
   PubMed Web of Science ®Google Scholar
• Reiman EM , ChenK, AlexanderGEet al.: Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer‘s dementia.Proc.Natl Acad. Sci. USA101, 284–289 (2004).
   PubMed Web of Science ®Google Scholar
• Reiman EM , UeckerA, CaselliRJet al.: Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer‘s disease.Ann. Neurol.44, 288–291 (1998).
   PubMed Web of Science ®Google Scholar
• Mosconi L , De Santi S, Brys Met al.: Hypometabolism and altered CSF markers in normal ApoE E4 carriers with subjective memory complaints. Biol. Psychiatry63, 609–618 (2008).
   PubMed Web of Science ®Google Scholar
• Geerlings MI , JonkerC, BouterLM, AderHJ, SchmandB: Associationbetween memory complaints and incident Alzheimer‘s disease in elderly people with normal baseline cognition.Am. J. Psychiat.156, 531–537 (1999).
   PubMed Web of Science ®Google Scholar
• Bobinski M , de Leon MJ, Convit Aet al.: MRI of entorhinal cortex in mild Alzheimer‘s disease. Lancet353, 38–40 (1999).
   PubMed Web of Science ®Google Scholar
• Cupples LA , FarrerLA, SadovnikAD, RelkinN, WhitehouseP, GreenP: Estimating risk curves for first-degree relatives of patients with Alzheimer‘s disease: The REVEAL study.Genet. Med.6, 192–196 (2004).
   PubMed Web of Science ®Google Scholar
• Green RC , CupplesLA, GoRet al.: Risk of dementia among white and African–American relatives of patients with Alzheimer disease.JAMA287, 329–336 (2002).
   PubMed Web of Science ®Google Scholar
• Silverman JM , CiresiG, SmithCJ, MarinDB, Schnaider-BeeriM: Variability of familial risk of Alzheimer disease across the late life span.Arch. Gen. Psychiat.62, 565–573 (2005).
   PubMed Web of Science ®Google Scholar
• Mosconi L , BrysM, SwitalskiRet al.: Maternal family history of Alzheimer‘s disease predisposes to reduced brain glucose metabolism.Proc. Natl Acad. Sci. USA104, 19067–19072 (2007).
   PubMed Web of Science ®Google Scholar
• Lin MT , BealMF: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.Nature443, 787–795 (2006).
   PubMed Web of Science ®Google Scholar
• Foster NL , HeidebrinkJL, ClarkCMet al.: FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer‘s disease.Brain130, 2616–2635 (2007).
   PubMed Web of Science ®Google Scholar
• Ishii K , SakamotoS, SasakiMet al.: Cerebral glucose metabolism in patients with frontotemporal dementia.J. Nucl. Med.39, 1875–1878 (1998).
   PubMed Web of Science ®Google Scholar
• Franceschi M , AnchisiD, PelatiOet al.: Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration.Ann. Neurol.57, 216–225 (2005).
   PubMed Web of Science ®Google Scholar
• Jeong Y , ChoSS, ParkJMet al.: 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients.J. Nucl. Med.46, 233–239 (2005).
   Google Scholar
• Diehl-Schmid J , GrimmerT, DrzezgaAet al.: Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study.Neurobiol. Aging28, 42–50 (2007).
   PubMed Web of Science ®Google Scholar
• Mosconi L , TsuiWH, HerholzKet al.: Multi-center standardized FDG-PET diagnosis of mild cognitive impairment, Alzheimer‘s disease and other dementias.J. Nucl. Med.49, 390–398 (2008).
   PubMed Web of Science ®Google Scholar
• Albin RL , MinoshimaS, D‘AmatoCJ, FreyKA, KuhlDE, SimaAAF: Fluoro-deoxyglucose positron emission tomography in diffuse lewy body disease.Neurol.47, 462–466 (1996).
   PubMed Web of Science ®Google Scholar
• Minoshima S , FosterNL, SimaAA, FreyKA, AlbinRL, KuhlDE: Alzheimer‘s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation.Ann. Neurol.50, 358–365 (2001).
   PubMed Web of Science ®Google Scholar
• McKeith IG , GalaskoD, KosakaKet al.: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop.Neurology47, 1113–1124 (1996).
   PubMed Web of Science ®Google Scholar
• Gilman S , KoeppeR, LittleRet al.: Differentiation of Alzheimer‘s disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing.Exp. Neurol.191, S95–S103 (2005).
   PubMed Web of Science ®Google Scholar
• Lockhart A : Imaging Alzheimer‘s disease pathology: one target, many ligands.Drug Discov. Today11, 1093–1099 (2006).
   PubMed Web of Science ®Google Scholar
• Herholz K : PET studies in dementia.Ann. Nucl. Med.17(2), 79–89 (2003).
   PubMed Web of Science ®Google Scholar
• DeCarli C , AtackJR, BallMJet al.: Post-mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional cerebral metabolic rates for glucose life in Alzheimer‘s disease patients.Neurodegeneration1, 113–121 (1992).
   Google Scholar
• Bradley KM , BydderGM, BudgeMMet al.: Serial brain MRI at 3–6 month intervals as a surrogate marker for Alzheimer‘s disease.Br. J. Radiol.75, 506–513 (2002).
   PubMed Web of Science ®Google Scholar
• Barber R , SnowdenJS, CraufurdD: Frontotemporal dementia and Alzheimer‘s disease: retrospective differentiation using information from informants.J. Neurol. Neurosurg. Psychiatry59, 61–70 (1995).
   PubMed Web of Science ®Google Scholar
• Ishii K , ImamuraT, SasakiMet al.: Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer‘s disease.Neurology51, 125–130 (1998).
   PubMed Web of Science ®Google Scholar
• Santens P , De Bleecker J, Goethals Pet al.: Differential regional cerebral uptake of 18F-fluoro-2-deoxy-D-glucose in Alzheimer‘s disease and frontotemporal dementia at initial diagnosis. Eur. Neurol.45, 19–27 (2001).
   PubMed Web of Science ®Google Scholar
• Higuchi M , TashiroM, AraiHet al.: Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies.Exp. Neurol.162, 247–256 (2000).
   PubMed Web of Science ®Google Scholar
• Klunk WE , EnglerH, NordbergAet al.: Imaging brain amyloid in Alzheimer‘s disease with Pittsburgh Compound-B.Ann. Neurol.55, 306–319 (2004).
   PubMed Web of Science ®Google Scholar
• Rowe CC , NgS, AckermannUet al.: Imaging β-amyloid burden in aging and dementia.Neurology68, 1718–1725 (2007).
   PubMed Web of Science ®Google Scholar
• Kemppainen N , AaltoS, WilsonIet al.: Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.Neurology67, 1575–1580 (2006).
   PubMed Web of Science ®Google Scholar
• Pike KE , SavageG, VillemagneVLet al.: β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer‘s disease.Brain130, 2837–2844 (2007).
   PubMed Web of Science ®Google Scholar
• Mintun MAM , LaRossaGN, ShelineYIMet al.: [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease.Neurology67, 446–452 (2006).
   PubMed Web of Science ®Google Scholar
• Fagan AM , MintunMA, MachRHet al.: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid.Ann. Neurol.59, 512–519 (2006).
   PubMed Web of Science ®Google Scholar
• Klunk WE , MathisCA, PriceJC, LoprestiBJ, DeKoskyST: Two-year follow-up of amyloid deposition in patients with Alzheimer‘s disease.Brain129, 2805–2807 (2006).
   PubMed Web of Science ®Google Scholar
• Drzezga A , GrimmerT, HenriksenGet al.: Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer‘s disease.Neuroimage39, 619–633 (2008).
   PubMed Web of Science ®Google Scholar
• Mathis CA , WangY, KlunkW: Imaging β-amyloid plaques and neurofibrillary tangles in the aging human brain.Curr. Pharm. Des.10, 1469–1492 (2004).
   PubMed Web of Science ®Google Scholar
• Lockhart A , LambJR, OsredkarTet al.: PIB is a non-specific imaging markerof amyloid-β (Aβ) peptide-related cerebral amyloidosis.Brain130, 2607–2615 (2007).
   PubMed Web of Science ®Google Scholar
• Agdeppa ED , KepeV, LiuJet al.: Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer‘s disease.J. Neurosci.21, 1–5 (2001).
   Web of Science ®Google Scholar
• Small GW , KepeV, ErcoliLMet al.: PET of brain amyloid and tau in mild cognitive impairment.N. Engl. J. Med.355, 2652–2663 (2006).
   PubMed Web of Science ®Google Scholar
• de Leon MJ , MosconiL, LoganJ: Seeing what Alzheimer saw.Nat. Med.13, 129–131 (2007).
   PubMed Web of Science ®Google Scholar
• Powell MR , SmithGE, KnopmanDSet al.: Cognitive measures predict pathologic Alzheimer disease.Arch. Neurol.63, 865–868 (2006).
   PubMedGoogle Scholar
• Rowe CC , AckermannU, BrowneWet al.: Imaging of amyloid β in Alzheimer‘s disease with 18F-BAY94–9172, a novel PET tracer: proof of mechanism.Lancet Neurol.7, 129–135 (2008).
   PubMed Web of Science ®Google Scholar
• Mosconi L , BrysM, Glodzik-SobanskaL, De Santi S, Rusinek H, de Leon MJ: Early detection of Alzheimer‘s disease using neuroimaging. Exp. Gerontol.42, 129–138 (2007).
   PubMed Web of Science ®Google Scholar
• Alexander GE , ChenK, PietriniP, RapoportSI, ReimanEM: Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer‘s disease treatment studies.Am. J. Psychiatry159, 738–745 (2002).
   PubMed Web of Science ®Google Scholar

Website

• Neuroimaging Initiative (ADNI) www.loni.ucla.edu/ADNI
   Google Scholar